// Workers AI · dad joke modeDoes Hotgen Biotech have genes for success?
Native name | |
|---|---|
| Simplified Chinese | 热景生物 |
| Traditional Chinese | 熱景生物 |
| Type | Public |
| SSE: 688068 | |
| Founded | 2005 |
| Founder | Changqing Lin |
| Headquarters | , |
| Revenue | CN¥5.369 billion (2021)[2] |
| Website | www |
Hotgen Biotech (short for Beijing Hotgen Biotech Co., Ltd.), often simply referred to as Hotgen,[3] is a Chinese biological technology company[4] founded in 2005. It focuses on the manufacture of in-vitro diagnostic instruments[5] and reagents.[6] In September 2019, the company was listed on the Shanghai Stock Exchange.[7] During the novel coronavirus pandemic, it specialized in making 2019-nCoV antigen diagnostic products,[8] which obtained EU CE certification.[9]
Hotgen was formerly a constituent of the STAR 50 Index.[10] Headquartered in Beijing, it also established presences in foreign markets, such as the United Kingdom,[11] France,[12] and Germany.[13] The net profit of the company in 2021 exceeded 2.3 billion yuan,[14] an increase of more than sixteen times from the previous year.[15] In 2022, its RAT kits were distributed free of charge[16] by the Hong Kong Government to the public.[17] In November 2023, it attended the MEDICA Trade Fair in Düsseldorf.[18]
History
[edit]Hotgen was established by Changqing Lin in 2005.[19] In September 2019, it went public on the STAR Market,[20] with stock symbol 688068.SH.[21] In early 2021, its COVID antigen self-test kits gained market access in Germany.[22]
As of April 2021, Hotgen's market cap surpassed RMB 10 billion.[23] In March 2022, its RAT products were approved by the NMPA.[24] In November, the Hotgen COVID-19 Antigen Home Test received an EUA from the FDA.[25]
References
[edit]- ↑ "China's Pharmaceutical Industry Growth Slows". Bloomberg. December 5, 2024.
{{cite web}}: CS1 maint: deprecated archival service (link) - ↑ Chen Xi (April 29, 2022). "Hotgen Biotech Announces 2021 Annual Report". Caixin.
{{cite web}}: CS1 maint: deprecated archival service (link) - ↑ "Interpretation of Financial Statements of Major Nucleic Acid Testing Companies in China". Sixth Tone. December 6, 2022. Archived from the original on November 8, 2023.
- ↑ Lu Han (2022). A Valuation of the Science and Technology Innovation Board in China. Cambridge Scholars Publishing. p. 104.
- ↑ Samuel Shen; David Stanway (January 22, 2020). "Shares of Chinese biotech firms and drug makers soar due to the COVID-19 pandemic". Reuters.
{{cite web}}: CS1 maint: deprecated archival service (link) - ↑ Donny Kwok (February 8, 2024). "Hotgen Biotech jumps on share buyback plan". Reuters.
{{cite web}}: CS1 maint: deprecated archival service (link) - ↑ "Hotgen Biotech set to debut on the Shanghai Stock Exchange on Sept 30". Reuters. September 26, 2019.
{{cite web}}: CS1 maint: deprecated archival service (link) - ↑ Emily DeLetter (January 4, 2024). "COVID-19 home tests can expire. How you can check expiration dates". USA Today. Archived from the original on January 16, 2024.
- ↑ Su Chongkai. "More Than 70% of Chinese A-Share Companies See Net Profit Growth in H1 2021". Yahoo News. September 2, 2021.
{{cite web}}: CS1 maint: deprecated archival service (link) - ↑ Yanhong Luo (August 31, 2020). "China's Economy Starts to Recover". The Wall Street Journal.
{{cite web}}: CS1 maint: deprecated archival service (link) - ↑ Cissy Zhou (February 18, 2022). "Chinese healthcare companies hit COVID jackpot with home-test kits". Nikkei Asia.
{{cite web}}: CS1 maint: deprecated archival service (link) - ↑ Jan van der Made (January 20, 2022). "Chinese producers outperform French competitors in the Covid-19 self-test market". Radio France Internationale. Archived from the original on January 28, 2022.
- ↑ Zhang Yunqing (April 29, 2022). "Germany officially enters the post-epidemic era". Deutsche Welle.
{{cite web}}: CS1 maint: deprecated archival service (link) - ↑ Qiu Liling (February 21, 2022). "China's antigen test kit makers see revenue surge". Yahoo News.
{{cite web}}: CS1 maint: deprecated archival service (link) - ↑ Kaiwen Xu. "Hotgen Biotech's 2021 Net Profit Soars More Than More Than 1600% YOY". Reuters. January 7, 2022.
{{cite web}}: CS1 maint: deprecated archival service (link) - ↑ Laura Westbrook; Sammy Heung (February 21, 2022). "Coronavirus Hong Kong: authorities to rely on self-test kits to diagnose infections". South China Morning Post. Archived from the original on February 26, 2022.
- ↑ "Crowds Scramble to Buy Cheap COVID-19 RAT Kits". Yahoo News. April 18, 2022.
{{cite web}}: CS1 maint: deprecated archival service (link) - ↑ "More than 1,400 Chinese exhibitors present at Medica 2023 in Germany". ANTARA News. November 14, 2023.
{{cite web}}: CS1 maint: deprecated archival service (link) - ↑ "Tsinghua alumni practically control 110 Chinese A-share public companies". Economic Daily. The Time Weekly. April 28, 2021.
{{cite web}}: CS1 maint: deprecated archival service (link) - ↑ Xie Yu (September 30, 2019). "Hong Kong market closes higher, as US-China trade war fears weigh on mainland Chinese stocks". South China Morning Post.
{{cite web}}: CS1 maint: deprecated archival service (link) - ↑ Zhang Yi (April 2, 2022). "Demand for Coronavirus Testing Continues to Surge". Caixin.
{{cite web}}: CS1 maint: deprecated archival service (link) - ↑ Haibo Song; Lizhong Dai (2023). In Vitro Diagnostic Industry in China. Springer. p. 571.
- ↑ Yanhong Luo (April 27, 2021). "Hotgen Biotech's Shares Surge 300% in a Month". The Wall Street Journal.
{{cite web}}: CS1 maint: deprecated archival service (link) - ↑ Xie Yu; Azar Zaidi (September 30, 2019). "Chinese COVID-19 RAT makers surge amid optimism about US$5.3 billion market". South China Morning Post.
{{cite web}}: CS1 maint: deprecated archival service (link) - ↑ "In Vitro Diagnostics EUAs - Antigen Diagnostic Tests for SARS-CoV-2". Food and Drug Administration. November 18, 2022.
{{cite web}}: CS1 maint: deprecated archival service (link)